Jan Hartmann: New Transformative Treatment for Hemophilia A
Jan Hartmann, Senior Vice President, Chief Medical Officer at Haemonetics, shared a post on LinkedIn:
”Congratulations to the team led by Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa of Chugai Pharmaceutical Co., Ltd. on being awarded the 2026 Lasker-DeBakey Clinical Medical Research Award for their pioneering development of a bispecific antibody that revolutionized the treatment of Hemophilia.
First approved in 2017 and subsequently licensed by Genentech, emicizumab (Hemlibra) provided a transformative new treatment option for people living with hemophilia A.
Beyond its impact on patient care, its success demonstrated the potential of bispecific antibodies as a therapeutic platform and helped catalyze the development of this modality across a wide range of diseases.”
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning